10 Jun

What Are Insulet’s Key Growth Drivers in 2019?

WRITTEN BY Margaret Patrick

Improving payer access

In the first quarter, Insulet (PODD) secured coverage for its Omnipod devices for 5 million Medicare and Medicaid members. According to the first-quarter earnings conference call, the company’s current coverage extends to more than one-third of Medicare beneficiaries and more than half of Medicaid beneficiaries. The company has also expanded coverage for its recently released Omnipod DASH system from 100 million covered patients at the end of fiscal 2018 to 130 million covered patients at the end of the first quarter.

Insulet has opted for the pharmacy channel to ensure the widespread distribution of Omnipod Dash. According to the first-quarter earnings conference call, the distribution of Omnipod DASH through Cardinal Health and the pay-as-you-go model are expected to be key growth drivers for this system in fiscal 2019. Currently, Omnipod DASH is the only insulin pump that does not lock patients into a four-year contract. Thus, the company has removed the constraint of high upfront costs for new users, thereby allowing them to access the technology prior to the expiry of their previous lock-in period. The distribution through the pharmacy channel and the pay-as-you-go model are also expected to prove beneficial to payers since it reduces their risk as well as the cost of member attrition.

Automated insulin delivery system

On June 9, Insulet issued a press release announcing positive results from a clinical trial evaluating the automated insulin delivery system, Omnipod Horizon, for improving glycemic control in pediatric type 1 diabetes patients in the age group of two years to six years.

According to the first-quarter earnings conference call, the company expects to begin pivotal trials for Omnipod Horizon in the fourth quarter of fiscal 2019. The company plans to launch this system in the second half of fiscal 2020.

According to the first-quarter earnings conference call, Insulet has also collaborated with Tidepool to create an open source iOS-based automated insulin delivery system, Tidepool Loop.

Direct operations in Europe

According to the first-quarter earnings conference call, to boost its international market presence, Insulet transitioned from a distributor-based to direct model in Europe in the second half of fiscal 2018. This strategy has already resulted in significant improvement in the company’s Net Promoter Score in Europe.

Latest articles

15 Jul

Will Amazon Prime Day 2019 Break 2018's Record?

WRITTEN BY Jitendra Parashar

This year, Amazon extended its Prime Day to 48 hours instead of the 36-hour sale in July 2018, making the 2019 event the longest Prime Day ever.

In a series of tweets on Monday, Trump today weighed in on China’s GDP growth, which came in at a 27-year low.

15 Jul

OrganiGram's Third-Quarter Earnings

WRITTEN BY Adam Jones

On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

Trump is reportedly planning to increase the content of US-made steel in federal projects, which would be a lifeline for US steel companies.

Huawei is preparing for “extensive layoffs” in the US, which could put the US-China trade deal on the rocks.

With Q2's Netflix earnings just around the corner, here's what you can expect from the online streaming giant and the broader streaming space.